Evidence map›Paper›PMID 26989188›Full record

ArticleBlood2016

Arf6 arbitrates fibrinogen endocytosis.

Matthew T Rondina, Andrew S Weyrich

Open access · greenAbstract readComment
In one paragraph

Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Matthew T RondinaUNIVERSITY OF UTAH; THE GEORGE E. WAHLEN DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER.ORCID http://orcid.org/0000-0003-3455-3730
Andrew S WeyrichUNIVERSITY OF UTAH; THE GEORGE E. WAHLEN DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER.
George E. Wahlen Department of VA Medical Center · US

Funding

Platelet Immune Responses in Aging and InfluenzaR01AG048022 · NIA · UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2014 to 2018
$1.8M
NIA NIH HHS R01 AG048022
6 · The paper itself

Abstract

In this issue of Blood, in a departure from studies of classic platelet function, Huang et al turn their attention to endocytosis and show that adenosine 5′-diphosphate-ribosylation factor 6 (Arf6) plays a key role in fibrinogen engulfment. Although platelets are known to bind, absorb, and load their granules with plasma proteins, this report is one of the first to explore mechanisms that control endocytosis in this anucleate cell. Huang et al demonstrate that Arf6-dependent endocytosis is restricted to fibrinogen, implying that Arf6 also modulates trafficking of αIIbβ3 integrins in platelets. Consistent with this notion, deletion of Arf6 in platelets enhances spreading on fibrinogen and accelerates clot retraction (see figure). However, activation of surface αIIbβ3 is unaffected, and Arf6 deficiency does not alter thrombosis in vivo. These incongruous results point toward the complexity of anucleate platelets and the need for more detailed studies to understand intracellular trafficking, recycling, and endocytosis in platelets and their precurs

Indexed as

ADP-Ribosylation FactorsAnimalsBlood PlateletsEndocytosisHumansPlatelet Glycoprotein GPIIb-IIIa ComplexADP-Ribosylation FactorsPlatelet Glycoprotein GPIIb-IIIa Complex

Identifiers

PMID26989188
PMCPMC4797018
OpenAlexW2323052162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.